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The intracellular levels of many proteins are regulated by ubiq-
uitin-dependent proteolysis. One of the best-characterized en-
zymes that catalyzes the attachment of ubiquitin to proteins is a
ubiquitin ligase complex, Skp1-Cullin-F box complex containing
Hrt1 (SCF). We sought to artificially target a protein to the SCF
complex for ubiquitination and degradation. To this end, we tested
methionine aminopeptidase-2 (MetAP-2), which covalently binds
the angiogenesis inhibitor ovalicin. A chimeric compound, protein-
targeting chimeric molecule 1 (Protac-1), was synthesized to recruit
MetAP-2 to SCF. One domain of Protac-1 contains the IkBa phos-
phopeptide that is recognized by the F-box protein b-TRCP,
whereas the other domain is composed of ovalicin. We show that
MetAP-2 can be tethered to SCFb-TRCP, ubiquitinated, and degraded
in a Protac-1-dependent manner. In the future, this approach may
be useful for conditional inactivation of proteins, and for targeting
disease-causing proteins for destruction.
Degradation of cellular proteins is required for normalmaintenance of cellular function, including proliferation,
differentiation, and cell death. One of the major pathways to
regulate proteins posttranslationally is ubiquitin-dependent pro-
teolysis. Ubiquitination occurs through the activity of ubiquitin-
activating enzymes (E1), ubiquitin-conjugating enzymes (E2),
and ubiquitin–protein ligases (E3), which act sequentially to
catalyze the attachment of ubiquitin to lysine residues of sub-
strate proteins (1). The E3s confer specificity to ubiquitination
reactions by binding directly to substrate. Although the exact
number of E3s cannot be determined with certainty from
sequence data, there are probably .100 distinct F-box-
containing E3s encoded within the human genome (2). One
particular class of E3s, the heterotetrameric Skp1-Cullin-F box
(SCF) complexes, consists of Skp1, a Cullin family member, the
RING-H2 protein Hrt1 (also known as Roc1 or Rbx1), and an
F box protein (3). These components are conserved from yeast
to mammals. The mammalian F box protein, b-TRCPyE3RS,
has been shown to bind IkBa, a negative regulator of NFkB (4).
The SCFb-TRCP complex promotes the ubiquitination and sub-
sequent degradation of IkBa, which results in activation of NFkB
during the inflammatory response (3).
The recruitment of IkBa to SCFb-TRCP is mediated by a 10-aa
peptide within IkBa, DRHDSGLDSM (4, 5). In response to
diverse inflammatory signals, IkBa kinase (IKK) phosphorylates
this motif on both serines, which triggers the binding of IkBa to
b-TRCP. Because it is a well-defined ligand for a specific
ubiquitin ligase, we sought to take advantage of this phos-
phopeptide to target an unrelated protein to SCFb-TRCP for
ubiquitination and degradation.
As proof of concept, we tested the ability of the IkBa
phosphopeptide (IPP) to target methionine aminopeptidase-2
(MetAP-2) to SCFb-TRCP. MetAP-2 catalyzes the cleavage of
N-terminal methionine from nascent polypeptides (6) and seems
to be the primary target of the potent angiogenesis inhibitors
fumagillin and ovalicin (OVA; refs. 7 and 8). Both of these
compounds inhibit MetAP-2 by covalently binding His-231 in the
active site. The consequent reduction in MetAP-2 activity is
thought to block endothelial cell proliferation by causing p53-
dependent arrest in the G1 phase of the cell cycle (9). Impor-
tantly, MetAP-2 is not known to be ubiquitinated or a substrate
for any SCF complex.
To determine whether MetAP-2 could artificially be targeted
to SCFb-TRCP, we synthesized proteolysis-targeting chimeric
molecule 1 (Protac-1) that contained both the IPP and OVA. We
hypothesized that the phosphopeptide moiety would bind
b-TRCP, and the OVA moiety would bind MetAP-2, thereby
recruiting MetAP-2 to SCFb-TRCP for ubiquitination (Fig. 1A).
We reasoned that this strategy might work because synthetic
ligands that link distinct proteins have been shown to be capable
of regulating signaling pathways in vivo (10). In this article, we
report that Protac-1 indeed binds MetAP-2 to SCFb-TRCP and
thereby promotes MetAP-2 ubiquitination and degradation.
Demonstrating that Protac-1 mediates the ubiquitination and
degradation of a foreign substrate by SCF provides a basis to
begin testing Protacs in vivo in addition to other targets known
to promote disease.
Materials and Methods
Synthesis of IkBa-OVA Protac. OVA (1.4 mmol) was dissolved in 10
ml of methanol at 0°C, and NaBH4 (3.0 mmol) was added slowly.
After 30 min of stirring, methanol was removed under reduced
pressure, and the resulting crude product was purified by flash
column chromatography to yield ovalicinol (1.15 mmol, 82%).
Fmoc-Gly was coupled to the ovalicinol to give Fmoc-Gly-
ovalicinol. Specifically, dimethylformamide (DMF, 28 ml) was
added to dichloromethane solution (30 ml) containing Fmoc-
Gly-OH (3.56 mmol) and oxalyl chloride (7.12 mmol) at 0°C.
After 3 hr of stirring at room temperature, dichloromethane was
removed under nitrogen atmosphere. The resulting solid residue
was redissolved in dichloromethane (10 ml) and was combined
with ovalicinol (0.6 mmol) and dimethylaminopyridine (4.7
mmol) in dichloromethane (30 ml) at 0°C. The reaction mixture
was stirred for 2 hr at room temperature. After dichloromethane
was removed under reduced pressure, the resulting residue was
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f lash-chromatographed to provide Fmoc-Gly-ovalicinol (0.39
mmol, 65%). Next, Fmoc-Gly-ovalicinol (0.09 mmol) was treated
with 20% piperidine in DMF (2 ml) at room temperature for 10
min, and the DMF was removed under high vacuum. The
resulting solid was redissolved in 2 ml of DMSO, and disuccin-
imidyl suberate (0.9 mmol) was added at room temperature.
After overnight stirring, DMSO was removed under high vac-
uum, and the resulting crude product was flash-chromato-
graphed to give monosuccinimidyl suberate-Gly-ovalicinol (0.06
mmol, 68%).
Monosuccinimidyl suberate-Gly-ovalicinol (12 mmol) in
DMSO (0.6 ml) was added to DMSO solution (1 ml) containing
IkBa peptide (3.67 mmol) and dimethylaminopyridine (11
mmol). After 20 min stirring at room temperature, the coupling
reaction was completed, which was confirmed by a Kaiser test.
DMSO was removed under high vacuum, and the resulting crude
product was repeatedly washed with dichloromethane and meth-
anol to remove excess monosuccinimidyl suberate-Gly-ovalicinol
to give the final product, IkBa peptide-suberate-Gly-ovalicinol
(5.8 mg, 2.59 mmol, 70%). The final product was characterized
by electrospray (ES) mass spectrometry. ES-MS (M 1 H)1 for
ovalicinol-Gly-suberate-IkBa peptideydimethylaminopyridine
was 2,231.56 Da. All other intermediates were characterized by
500-MHz 1H NMR spectroscopy.
MetAP-2–Protac-1 Coupling Assay. MetAP-2 (9 mM) was incubated
with increasing concentrations of Protac-1 (dissolved in water)
at room temperature for 45 min. Reactions were supplemented
with SDS loading dye, fractionated on an SDSy10% polyacryl-
amide gel, transferred onto a nitrocellulose membrane, and
immunoblotted with rabbit polyclonal anti-MetAP-2 antiserum
(Zymed). Enhanced chemiluminescence was performed by using
Amersham Pharmacia detection reagents.
Tissue Culture and Transfections. 293T cells were cultured in DMEM
with 10% (volyvol) FBS (GIBCO), penicillin (100 unitsyml), strep-
tomycin (100 mgyml), and L-glutamine (2 mM). Cells were split 1:5
before the day of transfection and transiently transfected with 40 mg
of plasmid. Cells were 60% confluent in 100-mm dishes on the day
of transfection. DNA [20 mg of pFLAG-Cul1(RDB1347) and 20 mg
of pFLAG-b-TRCP(RDB1189)] was added and the cells were
transfected using calcium phosphate precipitation, as described
(11). Cells were harvested 30 hr after transfection. Five micrograms
of pGL-1, a plasmid containing the cytomegalovirus (CMV) pro-
moter linked to the green fluorescent protein (GFP) cDNA, was
cotransfected into cells at the same time to assess transfection
efficiency. In all experiments, greater than 80% of the cells were
GFP-positive at the time of harvesting.
Immunoprecipitation and Ubiquitination Assays. 293T cell pellets
were lysed with 200 ml of lysis buffer (25 mM TriszCl, pH 7.5y150
mM NaCly0.1% Triton X-100y5 mM NaFy0.05 mM EGTAy1
mM PMSF). Pellets from cells transfected with vector, pFLAG-
b-TRCP, or pFLAG-Cul-1 were vortexed for 10 sec, then
incubated on ice for 15 min. After centrifugation at 13,000 rpm
in an Eppendorf microfuge (Germany) for 5 min at 4°C, the
supernatant was added to 20 ml of FLAG M2 beads (Sigma),
which were washed with lysis buffer three times before immu-
noprecipitation. Lysates were incubated with the beads on a
rotator for 2 hr at 4°C, followed by one wash with buffer A (25
mM Hepes buffer, pH 7.4y0.01% Triton X-100y150 mM NaCl)
and one wash with buffer B (the same buffer without the Triton
X-100). For binding assays (Fig. 3), 50% (10 ml) of the 9 mM
MetAP-2y50 mM Protac-1 mixture was loaded as input; the
other 50% was added to the beads. After the addition of ligand,
the beads were rotated at room temperature for 1 hr. The beads
were washed once each with buffers A and B. After centrifuga-
tion at 13,000 rpm in an Eppendorf microfuge (Germany) for 1
min, half of the bead and supernatant fractions, representing
bound and unbound, respectively, were evaluated by Western
blotting as described above. For ubiquitination reactions, 4 ml of
18 mM MetAP-2, 4 ml of 100 mM Protac-1, 0.5 ml of 0.1 mgyml
purified mouse E1, 1 ml of 0.5 mgyml human Cdc34 E2, and 1 ml
of 25 mM ATP were added to 20 ml (packed volume) of washed
FLAG-M2 beads. For competition experiments, the IPP (100
mM final) or OVA (100 mM final) was added simultaneously with
the Protac-1. Reactions were incubated for 1 hr at 30°C in a
thermomixer (Eppendorf) with constant mixing. SDSyPAGE
loading buffer was added to terminate reactions, which were
evaluated by Western blotting as described above.
The experiments performed herein used two different prep-
arations of MetAP-2. One preparation consisted primarily of a
47-kDa fragment that was generated either by a contaminating
protease or by slow autoproteolysis. The second preparation
consisted almost entirely of full-length 67-kDa MetAP-2. Es-
sentially identical results were obtained with both preparations.
Degradation Experiments with Xenopus Extracts. Extracts from
unfertilized Xenopus laevis eggs were prepared the day of the
experiment, as described (12). The MetAP-2–Protac-1 mixture
(4 ml of 9 mM MetAP-2 plus 50 mM Protac-1) or MetAP-2 alone
was added to 10 ml of extract in addition to OVA (10 mM final),
constitutively active IKK (IKK-EE, 0.4 mg), and okadaic acid
(OA; 10 mM final). N-acetyl-leu-leu-norleucinal (LLnL, 50 mM
final), epoxomicin (10 mM final), or DMSO vehicle were added
to the indicated concentrations to inhibit degradation by the
proteasome. The protease inhibitors chymostatin, pepstatin, and
A
B
Fig. 1. (A) Protac-1 targets MetAP-2 to SCF. Protac-1 is a chimeric molecule
that consists of a phosphopeptide moiety and a small molecule moiety that
interacts with the protein target. Ub, ubiquitin; H, Hrt1. (B) The synthesis
scheme for Protac-1 (see Materials and Methods). Fmoc, fluorenylmethoxy-
carbonyl; DMF, dimethylformamide; DMAP, dimethylaminopyridine; DSS, dis-
uccinimidyl suberate.
Sakamoto et al. PNAS u July 17, 2001 u vol. 98 u no. 15 u 8555
BI
O
CH
EM
IS
TR
Y
leupeptin (15 mgyml final concentration) also were added to the
extracts. Reactions were incubated for the indicated times at
room temperature and terminated by adding 50 ml of SDSy
PAGE loading buffer. Samples were evaluated by Western
blotting as described above.
Results
MetAP-2 Specifically Binds Protac-1 in Vitro. The IkBa-OVA chi-
mera, Protac-1 (Fig. 1B), was synthesized as described in Mate-
rials and Methods. To demonstrate that purified MetAP-2 bound
Protac-1, we incubated MetAP-2 (18 mM) with increasing con-
centrations of Protac-1 (Fig. 2A). A Western blot analysis was
performed with anti-MetAP-2 antiserum. At Protac-1 concen-
trations of 10 mM and 10 mM, we observed two bands; the lower
band represents unbound MetAP-2, and the upper band repre-
sents a complex of MetAP-2 bound to Protac-1. The addition of
Protac-1 at higher concentrations did not increase the yield of
MetAP-2–Protac-1 complexes, suggesting that only a fraction of
the MetAP-2 molecules were active and able to bind Protac-1.
Combining MetAP-2 with either free IPP or free OVA did not
yield the doublet observed with Protac-1. We also tested the
specificity of MetAP-2 interaction with Protac-1 in vitro. Free
OVA, but not free IPP, inhibited the formation of the MetAP-
2–Protac-1 complex (Fig. 2B). Therefore, our results demon-
strate that MetAP-2 was specifically conjugated to the OVA
moiety of Protac-1 in a concentration-dependent manner.
Protac-1 Recruits MetAP-2 to SCF. Before testing the activity of
Protac-1, we first adapted an approach to isolate and assay
SCFb-TRCP complexes in vitro as described (13). Lysates from
293T cells transfected with plasmids that encoded b-TRCP and
Cul-1 proteins tagged with the FLAG epitope at the N terminus
were immunoprecipitated with anti-FLAG antibody-conjugated
resin. Immunoblot analysis confirmed that all components of
SCFb-TRCP were present in the anti-FLAG immunoprecipitate,
including Skp1, Hrt1, and the transfected FLAGCul-1 and FLAGb-
TRCP (data not shown). Furthermore, control experiments
confirmed that these immunoprecipitates promoted ubiquitina-
tion of IKK-phosphorylated glutathione S-transferase-IkBa in a
manner that was inhibited by the IPP and Protac-1 (data not
shown; ref. 7).
To determine whether Protac-1 could recruit MetAP-2 to
SCFb-TRCP, we first incubated MetAP-2 (18 mM) with Protac-1
(100 mM) for 45 min at room temperature. After isolation of
SCFb-TRCP complexes, the anti-FLAG beads were supplemented
with the MetAP-2–Protac-1 mixture and rotated at room tem-
perature for 1 hr. The beads and supernatant then were evalu-
ated by Western blot analysis for the presence of MetAP-2.
Anti-FLAG beads coated with SCFb-TRCP, but not control beads
preincubated with untransfected 293T cell lysates, specifically
retained a fraction of the MetAP-2–Protac-1 complex and not
the unliganded MetAP-2 (Fig. 3). These results demonstrate that
Protac-1 specifically recruited MetAP-2 to SCFb-TRCP.
Protac-1 Mediates the Ubiquitination of MetAP-2. Because Protac-1
was able to tether MetAP-2 to SCFb-TRCP, we next asked whether
MetAP-2 could be ubiquitinated. To answer this question, we
supplemented anti-FLAG beads coated with SCFb-TRCP with
ATP, MetAP-2–Protac-1, plus purified E1, E2 (human Cdc34),
and ubiquitin. After incubation, Western blot analysis was
performed with anti-MetAP-2 antiserum. This experiment was
repeated with two different preparations of purified MetAP-2:
one contained primarily a 47-kDa autocatalyzed cleavage prod-
uct (Fig. 4A), and the other contained full-length 67-kDa protein
(Fig. 4B). In both cases, MetAP-2–Protac-1 was extensively
modified in the presence of SCFb-TRCP-coated beads but not
control beads (Mock). Substitution of the methyl ubiquitin,
which acts as a chain-terminator of polyubiquitination, collapsed
the high molecular weight forms of modified MetAP-2 to a series
of 2–3 bands migrating directly above unmodified MetAP-2–
Protac-1 complex (Fig. 4C, compare lanes 2 and 3 with lane 4),
confirming that MetAP-2 was ubiquitinated by SCFb-TRCP.
We next tested whether MetAP-2 ubiquitination depended on
Protac-1. As shown in Fig. 4C, MetAP-2 was not ubiquitinated
in the absence of either SCFb-TRCP (lane 1) or Protac-1 (lanes 5
or 6; for some experiments, methyl ubiquitin was used in place
of ubiquitin to simplify detection of ubiquitin conjugates).
Moreover, unlinked OVA (50 mM) plus IPP (50 mM) were not
able to substitute for the OVA–IPP conjugate (lane 7). Protac-
Fig. 2. MetAP-2 binds Protac specifically and in a concentration-dependent manner. (A) MetAP-2 (9 mM) was incubated with increasing concentrations of
Protac-1 at room temperature for 45 min. The last two lanes depict MetAP-2 that was incubated with either free IPP (50 mM) or free OVA (50 mM), as indicated.
After incubation, samples were supplemented with SDSyPAGE loading buffer, separated by SDSyPAGE, and immunoblotted with MetAP-2 antiserum. (B) Same
as A, except MetAP-2 (9 mM) plus Protac-1 (10 mM) were supplemented with either IPP (50 mM) or OVA (50 mM), as indicated. Protac binding to MetAP-2 was
inhibited by the addition of OVA, but not by the addition of IPP.
Fig. 3. Protac-1 recruits MetAP-2 to SCFb-TRCP. Extracts from 293T cells
transiently transfected with either control vector or plasmids expressing FLAG
epitope-tagged Cul-1 and b-TRCP were subject to affinity purification on
anti-FLAG resin to yield either control beads or SCFb-TRCP beads. The matrices
then were mixed with the preformed MetAP-2–Protac-1 complex (input),
incubated, and separated into pellet (bound) and unbound (sup) fractions.
Proteins were fractionated on an SDSy10% polyacrylamide gel, and immuno-
blotted with anti-MetAP-2 antiserum. MetAP-2 and MetAP-2–Protac-1 refer
to free MetAP-2 and MetAP-2 complexed with Protac-1, respectively.
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1-dependent ubiquitination of MetAP-2 was specific; it was
readily competed for by free IPP (Fig. 4D, lane 3 vs. lane 2). In
contrast, free OVA did not compete (Fig. 4D, lane 4), presum-
ably because it was unable to displace the Protac-1 that previ-
ously was linked covalently to MetAP-2. Taken together, these
observations indicate that Protac-1 specifically elicited ubiquiti-
nation of MetAP-2 by SCFb-TRCP, and that successful targeting
required that the two components of Protac-1 be bound together
as a chimeric molecule.
MetAP-2–Protac-1 Is Degraded in Xenopus Egg Extracts. The exper-
iments described above demonstrated that MetAP-2 was ubi-
quitinated in a Protac-1-dependent manner by highly purified
SCFb-TRCP. However, the key issues are whether Protac-1 can
specifically activate MetAP-2 degradation, and whether targeted
degradation can be achieved by endogenous ubiquitiny
proteasome pathway components at typical intracellular con-
centrations. To address these questions, we preincubated
MetAP-2 with Protac-1 to allow the complexes to form, and then
added the mixture to Xenopus egg extract supplemented with
IKK-EE (14), OA, and OVA. The addition of IKK-EE and OA
was intended to sustain phosphorylation of the IkBa peptide
moiety of Protac-1, whereas OVA was added to prevent the
further linkage of Protac-1 to MetAP-2. Remarkably, MetAP-
2–Protac-1 complex (top band) but not MetAP-2 alone (bottom
band) was mostly degraded after 30 min (Fig. 5). Degradation of
MetAP-2–Protac-1 was attenuated in extracts supplemented
with the proteasome inhibitors LLnL or epoxomicin (15), but not
by other protease inhibitors (chymotrypsin, pepstatin, and leu-
peptin) added to the reaction. Moreover, addition of both IKK-EE
and OA was required for optimal degradation of MetAP-2–
Protac-1. Similarly, we have seen specific turnover of the MetAP-
2–Protac-1 complex, but not free MetAP-2, in three independent
experiments. Because the IPP does not have lysines and the OVA
does not have free amino groups, it is unlikely that Protac itself
serves as a target for ubiquitin-dependent proteolysis. Taken to-
gether, these results suggest that Protac-1 targeted MetAP-2 for
degradation by means of the proteasome. MetAP-2 turnover
seemed to be very specific, in that maximal degradation required
agents predicted to sustain phosphorylation of the IkBa peptide.
Discussion
Because degradation of ubiquitinated proteins occurs rapidly in
cells, we reasoned that ubiquitin-dependent proteolysis might
provide an effective means to modulate the phenotype of normal
and diseased cells. Thus, we sought to develop a method to target
Fig. 4. Protac mediates MetAP-2 ubiquitination by SCF. (A) Ubiquitination of
the 46-kDa fragment of MetAP-2. MetAP-2–Protac-1 mixture was added to
either control (Mock) or SCFb-TRCP beads (1) supplemented with ATP plus
purified E1, E2 (Cdc34), and ubiquitin. The E2, UbcH5c (500 ng), was also tested
in the reaction, which resulted in the same degree of ubiquitination as
observed with Cdc34 (data not shown). Reactions were incubated for 1 hr at
30°C and were evaluated by SDSyPAGE followed by Western blotting with
anti-MetAP-2 antiserum. (B) Ubiquitination of full-length (67-kDa) MetAP-2.
Same as A, except that the 67-kDa preparation of MetAP-2 was used, and E1,
E2, plus ubiquitin were either added at normal (1X) or 2-fold higher (2X) levels,
as indicated. (C) Ubiquitination of MetAP-2 by SCFb-TRCP depends on Protac-1.
Same as A, except that methylubiquitin (Me) was substituted for ubiquitin, as
indicated, and the reactions depicted in lanes 5–7 lacked Protac-1. In lane 7,
unlinked IPP and OVA were added at 100 mM in place of Protac-1. (D)
Protac-1-dependent ubiquitination of MetAP-2 is competitively inhibited by
IPP. Same as A, except that reactions in lanes 3 and 4 were supplemented with
100 mM each IPP and OVA, respectively.
Fig. 5. MetAP-2-Protac is degraded in Xenopus extracts. The MetAP-2–
Protac-1 mixture or MetAP-2 alone was added to Xenopus egg extract forti-
fied with OVA (100 mM), IKK-EE (0.4 mg), and OA (10 mM). Where indicated,
reactions were either deprived of IKK-EE or OA, or were further supplemented
with 50 mM LLnL or 10 mM epoxomicin (Epox). Reactions were incubated for
the indicated times at room temperature, terminated by adding SDSyPAGE
loading buffer, and evaluated by SDSyPAGE followed by Western blotting
with anti-MetAP-2 antiserum.
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proteins, at will, to the ubiquitinyproteasome pathway. The
linchpin of the strategy described here is the development of
chimeric molecules—referred to as Protacs—that link a desired
target protein to a ubiquitin ligase. A related method for
regulated activation and termination of signaling pathways with
synthetic ligands has been described (10). As a target protein for
a proof of principle experiment, we chose MetAP-2, which
covalently binds the angiogenesis inhibitor OVA. For the ubiq-
uitin ligase, we chose the SCFb-TRCP complex, for reasons
described in more detail below. Although MetAP-2 has 36
lysines, it has not been reported to be an unstable protein in vivo,
and it was not clear whether it would serve as a substrate for
SCFb-TRCP, or whether it would be degraded by the ubiquitiny
proteasome pathway (16). Our results suggest that Protac-1 in
fact can recruit MetAP-2 to SCFb-TRCP for ubiquitination. In
addition, we report that Protac-1 specifies degradation of
MetAP-2 by the endogenous ubiquitinyproteasome pathway in
Xenopus egg extracts.
We selected SCFb-TRCP as a candidate ubiquitin ligase for the
development of Protac technology for two reasons. First, the
apparent constitutive activity of SCF complexes (3) enables a
general strategy to manipulate normal or diseased cells. Second, the
mechanism underlying substrate selection is well understood for
SCFb-TRCP. Pioneering work by Ben-Neriah and coworkers (4, 5)
demonstrated that a 10-aa internal phosphopeptide mediates ubiq-
uitination and degradation of IkBa. Subsequently, it was estab-
lished that b-TRCP is the receptor that links this phosphopeptide
to the ubiquitinyproteasome pathway (4, 17). Furthermore, while
our work was underway, Zhou, Howley, and colleagues (18) dem-
onstrated that engineered SCF complexes can be used to target
heterologous proteins for destruction. Zhou et al. fused the human
papillomavirus E7 protein to the F-box proteins Cdc4 and b-TRCP
to create chimeras, which assemble to form hybrid SCFCdc4-E7 and
SCFb-TRCP-E7 complexes. E7 binds tightly to retinoblastoma protein
(Rb), and the F-box proteinyE7 chimeras stimulate turnover of Rb
by means of the SCF pathway in both yeast and mammalian cells.
A limitation of the F-box fusion approach is that it depends on gene
transfer of the chimeric F-box protein; thus, its use is limited to
transgenic organisms. Its potential use as a therapeutic strategy
awaits the development of safe and reliable gene therapy protocols.
We propose that Protacs may be useful research tools for
manipulating the phenotype of cells by means of the targeted
elimination of specific proteins, or as useful therapeutic agents for
targeting the elimination of disease-promoting proteins. An obsta-
cle to realizing these goals, however, is that the phosphopeptide-
containing Protac-1 described here is unlikely to penetrate cells.
For future applications, Protacs will need to be modified to enhance
delivery to cells. For example, attachment of the tat peptide (19)
may promote transduction of Protac-1 into cells, or a b-TRCP-
binding peptide that is derived from the HIV Vpu protein (20, 21),
and that is phosphorylated by constitutively active casein kinase II
may allow delivery of an unphosphorylated Protac to cells. The
ultimate goal is to identify small molecules that can substitute for
the E3 targeting activity of the IPP.
We envision the potential to develop an entire suite of Protac
compounds (Fig. 6). Several approaches have been developed
for identifying small molecules that bind to any target protein of
interest (22–24). Candidates emerging from such screens would
serve as platforms for the production of new Protacs, regardless
of the topology of their interaction with the target protein.
Because the human genome encodes a large number of RING-
and HECT-based ubiquitin ligases, it should be possible to
develop multiple Protacs that target a single protein to allow for
fine-tuning its rate of degradation. Moreover, because some
ubiquitin ligases are likely to exhibit restricted patterns of
expression, it even may be possible to develop Protac-based
drugs whose effects are limited to specific tissues.
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